919 Stock Overview
Manufactures and sells pharmaceutical products and medical devices in China.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 1/6 |
Financial Health | 6/6 |
Dividends | 2/6 |
Jinling Pharmaceutical Company Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥6.96 |
52 Week High | CN¥10.13 |
52 Week Low | CN¥5.38 |
Beta | 0.47 |
1 Month Change | 0% |
3 Month Change | 3.26% |
1 Year Change | -12.56% |
3 Year Change | -8.06% |
5 Year Change | -4.40% |
Change since IPO | -49.71% |
Recent News & Updates
Recent updates
Shareholder Returns
919 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | -0.9% | -2.0% | -1.5% |
1Y | -12.6% | -13.0% | -11.8% |
Return vs Industry: 000919 matched the CN Pharmaceuticals industry which returned -13% over the past year.
Return vs Market: 000919 matched the CN Market which returned -11.8% over the past year.
Price Volatility
919 volatility | |
---|---|
919 Average Weekly Movement | 4.2% |
Pharmaceuticals Industry Average Movement | 5.5% |
Market Average Movement | 6.6% |
10% most volatile stocks in CN Market | 10.0% |
10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 000919 has not had significant price volatility in the past 3 months.
Volatility Over Time: 000919's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 4,871 | n/a | jlyy1999.com |
Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products and medical devices in China. The company provides Mailuoning injection/oral solutions for the treatment of thromboangiitis obliterans, arteriosclerosis obliterans, cerebral thrombosis and sequelae, polyarteritis, acute arterial embolism of extremities, diabetic gangrene, intravenous thrombus, thrombophlebitis, etc.; ferrous succinate tablets for the prevention and treatment of iron deficiency anemia; lentinan injection for the treatment of malignant tumors; and absorbable gelatin sponges for the treatment of wound hemostasis. It also offers medical and health care services.
Jinling Pharmaceutical Company Limited Fundamentals Summary
919 fundamental statistics | |
---|---|
Market cap | CN¥4.38b |
Earnings (TTM) | CN¥99.61m |
Revenue (TTM) | CN¥2.82b |
44.0x
P/E Ratio1.6x
P/S RatioIs 919 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
919 income statement (TTM) | |
---|---|
Revenue | CN¥2.82b |
Cost of Revenue | CN¥2.22b |
Gross Profit | CN¥606.44m |
Other Expenses | CN¥506.83m |
Earnings | CN¥99.61m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.16 |
Gross Margin | 21.48% |
Net Profit Margin | 3.53% |
Debt/Equity Ratio | 0% |
How did 919 perform over the long term?
See historical performance and comparisonDividends
1.4%
Current Dividend Yield51%
Payout RatioDoes 919 pay a reliable dividends?
See 919 dividend history and benchmarksJinling Pharmaceutical dividend dates | |
---|---|
Ex Dividend Date | May 31 2024 |
Dividend Pay Date | May 31 2024 |
Days until Ex dividend | 1 day |
Days until Dividend pay date | 1 day |
Does 919 pay a reliable dividends?
See 919 dividend history and benchmarks